Arima Hidetoshi, Motoyama Keiichi, Higashi Taishi
Department of Physical Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University.
Yakugaku Zasshi. 2019;139(3):385-391. doi: 10.1248/yakushi.18-00177-5.
Sacran, a new polysaccharide isolated from cyanobacterium Aphanothece sacrum (Sur.) Okada, is known to have potential as an active pharmaceutical ingredient (API) for the treatment of atopic dermatitis, various types of dermatitis, skin wound, hemorrhoids and corneal epithelium disorder. In the present studies, the effects of sacran on skin injury and skin pain induced by stratum corneum tape-stripping and gastric ulcer induced by indomethacin, a non-steroidal anti-inflammatory drug (NSAID), and hydrochloride/ethanol (HCl/EtOH) in mice were investigated. Sacran solution 0.05% (w/v) showed greater reduction of skin injury and skin pain induced by stratum corneum tape-stripping, compared to that of 0.01% (w/v) and 0.1% (w/v) sacran solutions. In addition, the inhibitory effects of 0.05% (w/v) sacran on skin injury and skin pain induced by tape-stripping were significantly superior to 0.05% (w/v) hyaluronic acid solution. On the other hand, 1.0% (w/v) sacran solution significantly inhibited gastric ulcer formation induced by indomethacin, compared with 1% (w/v) dextran solution and the inhibitory effect of sacran was comparable to that of the positive control omeprazole. In addition, 1% (w/v) and 2% (w/v) sacran solution reduced HCl/EtOH-induced gastric ulcer in mice, with the alleviative effect of sacran was comparable to or greater than that of the positive control sodium alginate. These results suggest that sacran has potential as API to treat skin injury and pain induced by tape-stripping and gastric ulcer induced by NSAIDs and EtOH.
Sacran是一种从蓝藻微囊藻中分离出来的新型多糖，已知它有潜力作为活性药物成分（API）用于治疗特应性皮炎、各类皮炎、皮肤伤口、痔疮和角膜上皮疾病。在本研究中，研究了Sacran对小鼠因角质层胶带剥离引起的皮肤损伤和皮肤疼痛、非甾体抗炎药（NSAID）吲哚美辛以及盐酸/乙醇（HCl/EtOH）诱导的胃溃疡的影响。0.05%（w/v）的Sacran溶液与0.01%（w/v）和0.1%（w/v）的Sacran溶液相比，对胶带剥离引起的皮肤损伤和皮肤疼痛有更大程度的减轻作用。此外，0.05%（w/v）的Sacran对胶带剥离引起的皮肤损伤和皮肤疼痛的抑制作用明显优于0.05%（w/v）的透明质酸溶液。另一方面，1.0%（w/v）的Sacran溶液与1%（w/v）的右旋糖酐溶液相比，能显著抑制吲哚美辛诱导的胃溃疡形成，且Sacran的抑制作用与阳性对照奥美拉唑相当。此外，1%（w/v）和2%（w/v）的Sacran溶液可减轻小鼠因HCl/EtOH诱导的胃溃疡，Sacran的缓解作用与阳性对照海藻酸钠相当或更强。这些结果表明，Sacran有潜力作为API用于治疗胶带剥离引起的皮肤损伤和疼痛以及NSAIDs和EtOH诱导的胃溃疡。
